Exane Derivatives’s Braskem BAK Stock Holding History

Exane Derivatives’s Portfolio BAK Stock Details BAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$30	–	677
2018 Q3	$30	Hold	1	–	–	﹤0.01%	657
2018 Q2	$26	Hold	1	–	–	﹤0.01%	659
2018 Q1	$27	Hold	1	–	–	﹤0.01%	596
2017 Q4	$26	Sell	1 -2	-67%	-$57	﹤0.01%	588
2017 Q3	$80	Sell	3 -32	-91%	-$786	﹤0.01%	518
2017 Q2	$725	Sell	35 -58	-62%	-$1.2K	﹤0.01%	491
2017 Q1	$1.89K	Buy	93 +14	+18%	+$295	﹤0.01%	393
2016 Q4	$1.68K	Hold	79	–	–	﹤0.01%	455
2016 Q3	$1.22K	Hold	79	–	–	﹤0.01%	477
2016 Q2	$936	Hold	79	–	–	﹤0.01%	424
2016 Q1	$1.02K	Sell	79 -535	-87%	-$6.83K	﹤0.01%	475
2015 Q4	$8.31K	Hold	614	–	–	﹤0.01%	341
2015 Q3	$5.18K	Sell	614 -4,758	-89%	-$36.7K	﹤0.01%	379
2015 Q2	$46.5K	Sell	5,372 -30,600	-85%	-$261K	0.01%	294
2015 Q1	$250K	Buy	35,972 +33,068	+1,139%	+$302K	0.03%	191
2014 Q4	$37.5K	Buy	+2,904	New	+$40.6K	0.01%	348

Other funds holding BAK

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCM

Contrarian Capital Management Greenwich, Connecticut $357M AUM 18.27% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return

Exane Derivatives's BAK Position: Q4 2018 in Review

Exane Derivatives sold out of Braskem (BAK) in Q4 2018, closing a stake of 1 share — an estimated $30 sold.

Exane Derivatives first reported a position in BAK in Q4 2014 and held it in 16 quarters. The position peaked at $250K in Q1 2015. 85 funds tracked by Wall St. Rank hold BAK as of Q4 2018.

Exane Derivatives reported no remaining Braskem position as of Q4 2018 after selling out during the quarter.
Exane Derivatives sold 1 Braskem share in Q4 2018, an estimated $30.
Exane Derivatives first reported a position in Braskem in Q4 2014 and held it in 16 quarters.
Exane Derivatives's Braskem position peaked at $250K in Q1 2015.
85 funds tracked by Wall St. Rank held Braskem as of Q4 2018.

Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.